Monogenic disease therapy developer Lexeo Therapeutics has publicly launched with financing from backers including Lundbeckfonden Ventures.

US-based gene therapy developer Lexeo Therapeutics has emerged from stealth with an oversubscribed $85m series A round featuring Lundbeckfonden Ventures, the strategic investment arm of pharmaceutical firm Lundbeck. The round was co-led by healthcare-focused venture capital firm Longitude Capital and investment firm Omega Funds and included life sciences real estate investment trust Alexandria Real Estate…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.